ALBUTEROL Drug Patent Profile
✉ Email this page to a colleague
When do Albuterol patents expire, and what generic alternatives are available?
Albuterol is a drug marketed by Armstrong Pharms, Genpharm, Ivax Sub Teva Pharms, Pliva, Cipla, Lupin, Padagis Us, Sandoz, Actavis Mid Atlantic, Apotex Inc, Bausch, Copley Pharm, Epic Pharma Llc, Landela Pharm, Luoxin Aurovitas, Mylan Speclt, Nephron, Ritedose Corp, Roxane, Sentiss, Sun Pharm, Teva Pharms, Watson Labs, Watson Labs Inc, Wockhardt Eu Operatn, Amneal Pharms, Chartwell Molecular, Chartwell Rx, Cosette, Hikma, Mova, Quagen, Teva, Rising, Aizant, Am Therap, Amneal Pharms Co, Aurobindo Pharma Ltd, Dash Pharms Natco, Eywa, Strides Pharma, Sun Pharm Industries, Ucb Inc, Virtus Pharm, Warner Chilcott, Zydus Pharms, Fosun Pharma, and Watson Labs Teva. and is included in eighty-four NDAs.
The generic ingredient in ALBUTEROL is albuterol sulfate; ipratropium bromide. There are thirty-eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the albuterol sulfate; ipratropium bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Albuterol
A generic version of ALBUTEROL was approved as albuterol sulfate; ipratropium bromide by CIPLA on December 31st, 2007.
Summary for ALBUTEROL
US Patents: | 0 |
Applicants: | 48 |
NDAs: | 84 |
Raw Ingredient (Bulk) Api Vendors: | 133 |
Clinical Trials: | 282 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ALBUTEROL |
Drug Sales Revenues: | Drug sales revenues for ALBUTEROL |
DailyMed Link: | ALBUTEROL at DailyMed |
Recent Clinical Trials for ALBUTEROL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Johns Hopkins University | Phase 3 |
Parexel | Phase 3 |
Geisinger Clinic | Early Phase 1 |